A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)
Phase of Trial: Phase III
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Adverse reactions
- Acronyms PREVENT
- Sponsors Alexion Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 19 Nov 2016 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 10 Dec 2013 New source identified and integrated: ClinicalTrials.gov record.